AtriCure target price raised to $67 from $55
ATRC•Canaccord Genuity raised its target price for AtriCure to $67 from $55.
Related News
JPMorgan Asset Management, affiliates hold 5.07% stake in Eugene Technology
JPM•
Ultragenyx Pharmaceutical: Canaccord Genuity cuts target price to $34 from $39
RARE•
Revvity, Inc.: Leerink Partners raises target price to $180 from $160
RVTY•
Rhythm Pharmaceuticals: Needham cuts target price to $114 from $130
RYTM•
MINISO files next day disclosure return with HKEX on share buyback for cancellation
MNSO•